Prostate Cancer P D:水蒸气热疗能够减轻导管依赖的尿滞留

2019-12-03 AlexYang MedSci原创

水蒸汽热疗通过利用对流传递的热能来靶向消融阻塞性前列腺组织。最近,有研究人员报道了该热疗方法在减轻与良性前列腺增生(BPH)相关的非神经性尿滞留上的结果情况。研究人员对38名导管依赖的男性进行了回顾性的分析,他们的平均年龄为75.5岁。研究发现,在治疗的38名患者中,1名患者在跟踪调查时丢失,剩下的37名中的26名(70.3%)能够自发的排尿(TWOCs均值为1.6±0.8),且热疗后不依赖导管的

水蒸汽热疗通过利用对流传递的热能来靶向消融阻塞性前列腺组织。最近,有研究人员报道了该热疗方法在减轻与良性前列腺增生(BPH)相关的非神经性尿滞留上的结果情况。

研究人员对38名导管依赖的男性进行了回顾性的分析,他们的平均年龄为75.5岁。研究发现,在治疗的38名患者中,1名患者在跟踪调查时丢失,剩下的37名中的26名(70.3%)能够自发的排尿(TWOCs均值为1.6±0.8),且热疗后不依赖导管的时间均值为26天(范围4-64天)。该26患者中的18名不连续BPH用药。年龄、前列腺体积、水蒸汽注射次数或者正中叶的存在方面没有发现显著的差异与预测成功的治疗结果相关。另外,20名不依赖导管的患者的跟踪调查时间均值为475天(140-804天);6名患者的跟踪调查时间均值为31.5天(0-60天)。副作用事件不常见且轻微,并且很快消失,包括了5名(13%)患者中的排尿困难,4名(10.5%)患者中的肉眼血尿和2名(2.6%)患者中的泌尿感染

最后,研究人员指出,水蒸气热疗能够为导管依赖尿滞留患者提供一种安全有效的手术治疗。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791595, encodeId=62331e9159555, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 27 17:36:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716740, encodeId=3ca31e167400a, content=<a href='/topic/show?id=147c6e238cf' target=_blank style='color:#2F92EE;'>#热疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67238, encryptionId=147c6e238cf, topicName=热疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=924b32313941, createdName=zhaohui6742, createdTime=Thu Jul 16 14:36:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364549, encodeId=162813645496c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602217, encodeId=09a5160221ed4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791595, encodeId=62331e9159555, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 27 17:36:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716740, encodeId=3ca31e167400a, content=<a href='/topic/show?id=147c6e238cf' target=_blank style='color:#2F92EE;'>#热疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67238, encryptionId=147c6e238cf, topicName=热疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=924b32313941, createdName=zhaohui6742, createdTime=Thu Jul 16 14:36:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364549, encodeId=162813645496c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602217, encodeId=09a5160221ed4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791595, encodeId=62331e9159555, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 27 17:36:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716740, encodeId=3ca31e167400a, content=<a href='/topic/show?id=147c6e238cf' target=_blank style='color:#2F92EE;'>#热疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67238, encryptionId=147c6e238cf, topicName=热疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=924b32313941, createdName=zhaohui6742, createdTime=Thu Jul 16 14:36:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364549, encodeId=162813645496c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602217, encodeId=09a5160221ed4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
    2019-12-05 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791595, encodeId=62331e9159555, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 27 17:36:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716740, encodeId=3ca31e167400a, content=<a href='/topic/show?id=147c6e238cf' target=_blank style='color:#2F92EE;'>#热疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67238, encryptionId=147c6e238cf, topicName=热疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=924b32313941, createdName=zhaohui6742, createdTime=Thu Jul 16 14:36:00 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364549, encodeId=162813645496c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602217, encodeId=09a5160221ed4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Dec 05 04:36:00 CST 2019, time=2019-12-05, status=1, ipAttribution=)]
    2019-12-05 sunylz

相关资讯

Oncogene:BRF1能够促进前列腺致瘤和干扰免疫浸润

BRF1是RNA聚合酶III介导转录的限速因子,并在多种癌症中表达上调。最近,有研究人员报道了BRF1表达的提高与人类前列腺癌不良的预后相关。人类前列腺癌细胞系体外研究阐释了BRF1的瞬时过表达能够增加细胞增殖,而BRF1的瞬时下调能够减少细胞增殖和介导细胞周期阻滞。与临床观察一致的是,Pten缺陷小鼠前列腺癌模型(PtenΔ/Δ BRF1Tg)中,BRF1的过表达能够促进前列腺癌的发生和缩短生存

Brit J Cancer:转移去势抵抗性前列腺癌中卡巴他赛治疗的总生存和无进展生存研究

卡巴他赛是多烯紫杉醇治疗去势抵抗性前列腺癌(mCRPC)失败后的一种治疗方法。FUJI群体旨在确定卡巴他赛在现实生活中总生存(OS)、无进展生存(PFS)和安全性情况。研究是一个多中心、非介入性群体研究,时间为2013年到2015年,跟踪调查时间为18个月。研究包括了42个中心的401名患者。入选患者的平均年龄为70岁,主要转移位点为骨组织(87%)、淋巴结(42%)和内脏(18%)。18%的患者

Prostate Cancer P D:本地美国患者前列腺癌特征和癌症特异死亡率研究

历史的流行病学数据表明了本地美国人可能有比白种人患者(CAP)具有更加严重的前列腺癌(PCa)特性。最近,有研究人员为了测试本地美国人与CAP之间癌症特异性死亡(CSM)的差异,使用了最新版本的SEER数据库对上述问题进行了探究。研究人员聚焦于357289名白种人和本地美国人PCa患者组合群体的描述和时间趋势分析。研究发现,本地美国人患者占研究群体的0.5%(1804名)。本地美国人患者与CAP相

默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期

根据默克公司第二阶段KEYNOTE-199研究的结果,默克公司(Merck)的重磅炸弹PD-1单抗Keytruda延长了一小部分晚期前列腺癌患者的生命。

Sci Rep:血清N-glycan是去势抵抗性前列腺的潜在生物标记

最近,有研究人员调查了血清N-glycan在去势抵抗性前列腺癌中的诊断和预后意义。研究人员回顾性的调查了287名良性前列腺增生(BPH)患者、289名新诊断前列腺癌(PC)患者、57名进行雄激素阻断治疗且无疾病恶化的PC患者(PC-ADT)和60名CRPC患者的糖印迹血清N-glycan结构分析情况,并比较了非CPRC患者(BPH、新诊断PC和PC-ADT)与CPRC患者的N-glycan情况。研

西安杨森宣布旗下新一代前列腺癌治疗方案安森珂®在华获批

2019年11月27日,强生公司在华制药子公司西安杨森制药有限公司今日宣布,旗下新一代雄激素受体抑制剂安森珂®(阿帕他胺片,英文商品名:Erleada®,apalutamide)在中国正式上市,用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)成年患者。此前,国家药品监督管理局药品审评中心(CDE)因安森珂®明显的临床优势授予其“优先审评”资格,并将安森珂®纳入第二批临床急需境外